Lentigen Corporation announces Sale of Lentiviral Vector Manufacturing Business and Change of Name to Opus Bio, Inc.
GREENWICH, Conn., Aug. 14, 2014 /PRNewswire/ — Lentigen Corporation, a global leader in lentiviral technology for cell and gene therapy applications, today announced the sale of its lentiviral vector manufacturing business and related assets to Miltenyi Biotec, who will operate through its newly formed, wholly-owned US subsidiary Lentigen Technology, Inc. based in Gaithersburg, MD.
In connection with the transaction, Lentigen Corporation has been renamed Opus Bio, Inc., and has been granted certain rights to deploy lentiviral technology in specified therapeutic indications, for which Lentigen Technology, Inc. shall be the preferred manufacturing supplier. These rights include specified CAR T-cell based therapies as well as specified therapies for single-gene diseases and disorders.
Chimeric antigen receptor T cell therapy (CAR+ T) technologies have made significant advances during the past several years, as evidenced by consistent clinical results reported by several academic teams. “We are pleased that Lentigen Corporation has been at the forefront of the lentiviral vector manufacturing innovation that has enabled these advances in the treatment of hematologic malignancies,” said David Wetherell, Chairman of Lentigen Corporation. He added, “this transaction will provide Opus Bio with ongoing access to innovations in lentiviral vector and cell processing technologies, while allowing the company to commit further resources toward the advancement its research and clinical development programs.”
Opus Bio intends to make further announcements on the progress of its therapeutic pipeline during the coming months.
Opus Bio is a clinical-stage biotechnology company committed to developing potentially transformative cell therapies for cancer and single gene disorders. The company is backed by Biomark Capital, a life sciences and healthcare investment firm with offices in Greenwich, CT and San Francisco, CA.
Investor and media contact:
Douglas D. Lind, MD
Interim Chief Executive Officer
Opus Bio, Inc.
SOURCE Opus Bio, Inc.